KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Free Cash Flow: 2020-2025

Historic Free Cash Flow for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$117.6 million.

  • Recursion Pharmaceuticals' Free Cash Flow fell 84.37% to -$117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$447.7 million, marking a year-over-year decrease of 34.73%. This contributed to the annual value of -$372.9 million for FY2024, which is 24.40% down from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Free Cash Flow is -$117.6 million, which was down 47.80% from -$79.6 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Free Cash Flow peaked at $73.0 million during Q1 2022, and registered a low of -$133.8 million during Q1 2025.
  • Moreover, its 3-year median value for Free Cash Flow was -$79.6 million (2025), whereas its average is -$91.2 million.
  • In the last 5 years, Recursion Pharmaceuticals' Free Cash Flow slumped by 1,443.06% in 2021 and then soared by 245.59% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Free Cash Flow (Quarterly) stood at -$65.6 million in 2021, then rose by 19.65% to -$52.7 million in 2022, then crashed by 44.41% to -$76.1 million in 2023, then tumbled by 53.30% to -$116.7 million in 2024, then crashed by 84.37% to -$117.6 million in 2025.
  • Its last three reported values are -$117.6 million in Q3 2025, -$79.6 million for Q2 2025, and -$133.8 million during Q1 2025.